Synergetics USA: A Growth Story Amidst An Aging Population [View article]
Yes, of course. It's common practice for publishers to syndicate their articles on the web; that's exactly what Investing Daily (parent web site for Personal Finance) does with the articles of all its authors, including my articles. You'll find that much of the content on Seeking Alpha originally appeared elsewhere. It's a very widespread practice -- and a useful one, both for publishers and readers. I'm editorial director of both Investing Daily and Personal Finance, and as you point out, I originally reported and wrote this article on SURG for Personal Finance.
Third Quarter Looking Rosy For Verizon [View article]
As Mr. Genachowski put it: "The [FCC approved] transaction will preserve incentives for deployment and spur innovation while guarding against anti-competitive conduct."
The M2M Money Machine: Digi International [View article]
Thank you for the compliment. I enjoy reporting and writing about dynamic small-cap companies with enormous growth potential that are innovators in technology.
EPD is still a buy up to 50. And yes, you should follow your instincts. Europe has its problems and you should remain defensive, but the euro zone's debt woes are no reason to panic and dump inherently strong stocks.
'Biological Legos' Could Become A Blockbuster Innovation For Osiris Therapeutics [View article]
Actually, I did some fact-checking and it turns out that this is not the reason. The report is erroneous; glad I could set the record straight. The real reason is that investors are concerned that the stock has had a huge run-up so far this year and is vulnerable for a fall.
'Biological Legos' Could Become A Blockbuster Innovation For Osiris Therapeutics [View article]
Osiris halted enrollment in a final stage trial of its Crohn's disease drug, triggering a drop in its stock price. It stopped enrollment of 210 patients in its Phase III trial evaluating its stem cell treatment Prochymal for Crohn's disease after higher than expected placebo response rates. However, the market has overreacted to this temporary bad news. The company is still fundamentally solid; this is a buying opportunity.
It's a large company in a depressed industry with current risks of products coming off patent. So far, the company's revenues from patent loss have not been replaced as fully as expected.
Tech Stocks: Leading The Way Forward [View article]
Home Depot: Cash Is Key To Dividend Growth [View article]
Battered FedEx Is Poised To Deliver [View article]
Home Depot: Cash Is Key To Dividend Growth [View article]
Synergetics USA: A Growth Story Amidst An Aging Population [View article]
Third Quarter Looking Rosy For Verizon [View article]
Smiths Group Gearing Up To Launch Record Number Of New Security Products [View article]
The M2M Money Machine: Digi International [View article]
The M2M Money Machine: Digi International [View article]
Growth Spotlight: Enterprise Products Partners LP [View article]
Growth Spotlight: Enterprise Products Partners LP [View article]
'Biological Legos' Could Become A Blockbuster Innovation For Osiris Therapeutics [View article]
'Biological Legos' Could Become A Blockbuster Innovation For Osiris Therapeutics [View article]
'Biological Legos' Could Become A Blockbuster Innovation For Osiris Therapeutics [View article]
Growth Spotlight: Novartis AG [View article]